Stock Analysis
Alnylam Pharmaceuticals, Inc.ALNY
P/E 38.39×· 5Y range 34.01–1,512.57×· bottom 9% of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy38 analystsP/E 38.4× sits at the 9th percentile of its 5.089664613278576-year history.
PMP Verdict
Mixed fundamentals, cheap valuation
Strengths
- Profitability65
Risks
- Growth50
- Financial Health50
Mixed business trading cheap — priced for skepticism.
Bull Case
- ✓Altman Z 4.3 — safe-zone balance sheet
- ✓ROE 102.4% — efficient capital deployment
- ✓Revenue CAGR 44.8% — durable top-line growth
- ✓P/E 38.4× at bottom 9% of 5-year history
What's happening with ALNY
Profile
moat lags behind.
How is each axis scored?
- Valuation52/100 · Moderate
- P/E vs own history (9th pct)25/25
- FCF yield (2.6%)5/25
- P/S (6.5x)12/25
- EV/EBIT (n/a)10/25
- Growth50/100 · Moderate
- Revenue CAGR (44.8%)25/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (37.0%)25/25
- Profitability65/100 · Moderate
- ROIC (n/a)0/25
- ROE (102.4%)25/25
- Net margin (16.8%)20/25
- Operating margin (20.8%)20/25
- Financial Health50/100 · Moderate
- Altman Z (4.30)25/25
- Current ratio (2.76)25/25
- Interest coverage (-1.2x)0/25
- Net cash / debt (n/a)0/25
- Quality57/100 · Moderate
- Piotroski F (5/9)15/25
- Beneish M (-2.34)20/25
- FCF conversion (98%)22/25
- Margin stability (σ 292.1%)0/25
- Moat25/100 · Weak
- ROIC >12% years (0/3 yrs)0/25
- Median gross margin (86.4%)25/25
- FCF-positive years (2/10 yrs)0/25
- Worst-year net margin (worst -1016.6%)0/25
Risk Flags
- ⚠SBC 7.0% of revenue — real dilution cost
- ⚠9 loss-making years in recent history
- ⚠Interest coverage -1.2× — thin debt cushion
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. Show more
RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Headquarters: CAMBRIDGE, MA · Employees: 2,500 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
52CP/E (TTM)38.4xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 34.0x–1512.6x · 9th pct
P/FCF37.8xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.6%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -4.6%–2.9% · 98th pct
P/S (TTM)6.46xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 5.7x–33.1x · 2nd pct
EV/EBITDA30.7xD
Grade D: ExpensiveEnterprise value / EBITDA (Finnhub) — capital-structure neutral — vs own 5Y history: 27.2x–55.8x · 13th pct
EV/Sales6.5xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E28.0xC
Grade C: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio39.31xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio0.66A
Grade A: CheapFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
65BROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE102.4%A
Grade A: StrongReturn on Equity. Neg. equity = heavy buybacks
ROA15.8%A
Grade A: StrongReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin16.8%A
Grade A: HighNet Income / Revenue
Operating Margin20.8%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin79.8%A
Grade A: PremiumGross Profit / Revenue
FCF Margin16.5%A
Grade A: HighFCF / Revenue
True FCF Margin9.5%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
50CRevenue CAGR44.8%A
Grade A: HighCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth37.0%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+13.9%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income41.7%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue7.0%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
50CAltman Z-Score4.30A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.76xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio2.79xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-1.2xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment—
Years to repay net debt via FCF
Net Debt/EBIT—
Leverage. <2x Low, >4x High
Debt/Equity2.02xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt—
Cash covers how much of total debt. >1 = could repay all debt from cash
Quality
57CPiotroski F-Score5/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.34A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion98.3%A
Grade A: StrongFCF / Net Income
Margin Stability292.1%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue1.9%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.94xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
SUPRAN BRYAN Filed | SUPRAN BRYAN | SellOpen market sale | -1758 | |
Greenstreet Yvonne Filed | Greenstreet Yvonne | Grant / award | +107 | |
Cravatt Benjamin Filed | Cravatt Benjamin | Grant / award | +4.4K | |
PYOTT DAVID E I Filed | PYOTT DAVID E I | Option exercise | -3830 | |
PYOTT DAVID E I Filed | PYOTT DAVID E I | SellOpen market sale | -17 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
PYOTT DAVID E I Filed | PYOTT DAVID E I | SellOpen market sale | -495 | |
PYOTT DAVID E I Filed | PYOTT DAVID E I | SellOpen market sale | -1222 | |
PYOTT DAVID E I Filed | PYOTT DAVID E I | SellOpen market sale | -1175 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
25EROIC >12% Years0/3 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)86.4%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years2/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-1016.6%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$6.04
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$24.74
Cash & short-term investments per share (Finnhub)
Book Value / Share$10.13
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt—
Total debt obligations (short + long term)
Cash & Equiv.$2.91B
Cash and short-term investments
Net Debt—
Total Debt minus Cash. Negative = Net Cash position
Total Equity$789.18M
Shareholders' equity (book value)
Asset / Liability1.19xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$31.02B
Current Market Capitalization
Beta0.37B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Alnylam Pharmaceuticals, Inc. (ALNY)
ALNY is down 0.94% at the last close. Piotroski F-Score of 5/9 indicates mixed fundamentals for Alnylam Pharmaceuticals, Inc.. Altman Z-Score of 4.30 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.34 suggests a low likelihood of earnings manipulation. Revenue has compounded at roughly 45% annually — a strong growth profile.
- Alnylam Pharmaceuticals, Inc. converts about 17% of revenue into free cash flow — strong cash generation.
- Interest coverage of -1.2× leaves little room for earnings shocks.
- Alnylam Pharmaceuticals, Inc. posted a net loss in 9 of 10 available completed fiscal years (2016–2025).
- Return on equity of 102.4% is well above the market average.
See how ALNY ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all ALNY moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 1 | Regular | 233.07 | -5.54% | -2.44 |
Frequently Asked Questions about ALNY
What is the current Alnylam Pharmaceuticals, Inc. (ALNY) stock price?
ALNY is trading at $231.83 at the last market close, down 0.94% on the session. PreMarketPrice tracks ALNY pre-market, intraday and after-hours prices.
Is ALNY stock a buy right now?
PreMarketPrice's quantitative model rates Alnylam Pharmaceuticals, Inc.'s financial health at 50/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is ALNY stock overvalued?
Alnylam Pharmaceuticals, Inc. trades at a trailing P/E of 38.4 and our valuation score rates it 52/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Alnylam Pharmaceuticals, Inc. report earnings?
No confirmed earnings date is currently scheduled for ALNY. The Earnings section lists recent reports and updates as dates are announced.
What sector does Alnylam Pharmaceuticals, Inc. operate in?
Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics.
About Alnylam Pharmaceuticals, Inc. (ALNY) Stock
Alnylam Pharmaceuticals, Inc. (ALNY) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Alnylam Pharmaceuticals, Inc. is trading at $231.83, down 0.94% on the day with a market capitalization of $31.0 billion. The financial health score for ALNY is 50/100, which indicates moderate financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for ALNY stock.
ALNY Stock Analysis & Key Metrics
On PreMarketPrice, you can track Alnylam Pharmaceuticals, Inc. (ALNY) across multiple dimensions:
- Pre-market price & movement: Real-time ALNY stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for ALNY with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Alnylam Pharmaceuticals, Inc. across multiple reporting periods.
- Financial health score: A composite score of 50/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for ALNY.
- Sector peers: Compare ALNY against 6 other healthcare stocks on key financial metrics.
Is ALNY a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Alnylam Pharmaceuticals, Inc. (ALNY) as an investment. The financial health score of 50/100 suggests moderate financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Alnylam Pharmaceuticals, Inc. (ALNY) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.